(Q38073718)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

New directions in immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Linda Cox

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Thomas Kundig

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mark Larche

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

Current Allergy and Asthma Reports

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

178-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315329%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11882-012-0335-7

22 February 2020

exact match

0 references

cites work

Costs of asthma in the United States: 2002-2007.

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

The diagnosis and management of rhinitis: an updated practice parameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Economic impact and quality-of-life burden of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Comparison of allergen immunotherapy practice patterns in the United States and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Adherence to sublingual immunotherapy in preschool children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Advances in transcutaneous vaccine delivery: do all ways lead to Rome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Friendly and dangerous signals: is the tissue in control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Epithelial decision makers: in search of the 'epimmunome'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

IL-33: a novel danger signal system in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Perception and practice of sublingual immunotherapy among practicing allergists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Allergen specific immunotherapy for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Treatment of peanut allergy with rush immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral desensitizing treatment in food allergy: clinical and immunological results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral desensitisation in cow milk allergy: immunological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Egg oral immunotherapy in nonanaphylactic children with egg allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral rush desensitization to egg: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral immunotherapy in hen's egg-allergic children increases a hypo-proliferative subset of CD4+ T cells that could constitute a marker of tolerance achievement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral immunotherapy for treatment of egg allergy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Successful oral tolerance induction in severe peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Oral peanut immunotherapy in children with peanut anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Peanut oral immunotherapy is not ready for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Sublingual desensitization in patients with wasp venom allergy: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Immunization without needles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Dissolving polymer microneedle patches for influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

In-vivo dynamic characterization of microneedle skin penetration using optical coherence tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Clinical administration of microneedles: skin puncture, pain and sensation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Delivery systems for intradermal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Microneedle technologies for (trans)dermal drug and vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Coated microneedle arrays for transcutaneous delivery of live virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Smallpox in history: the birth, death, and impact of a dread disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Lympho-geographical concepts in vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Intralymphatic immunotherapy: from the rationale to human applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Intralymphatic injections as a new administration route for allergen-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Vaccination with genetically engineered allergens prevents progression of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Safety of engineered allergen-specific immunotherapy vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Immunoregulation by targeting T cells in the treatment of allergy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

The safety and efficacy of ALLERVAX CAT in cat allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Specific oral tolerance induction in children with very severe cow's milk–induced reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Skin immunization made possible by cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0335-7

Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome

21 January 2018

1 reference

12 December 2020

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents

1 reference

12 December 2020

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

1 reference

12 December 2020

Treatment of cat allergy with T-cell reactive peptides

1 reference

12 December 2020

Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey

1 reference

12 December 2020

T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2

1 reference

12 December 2020

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

1 reference

12 December 2020

A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy

1 reference

12 December 2020

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

1 reference

12 December 2020

Co-seasonal treatment of pollinoses in Portugal with the method of cutaneous grids

1 reference

12 December 2020

Allergen-specific immunotherapy with recombinant grass pollen allergens

1 reference

12 December 2020

Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract--a new therapeutic option for patients with atopic dermatitis

1 reference

12 December 2020

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

1 reference

12 December 2020

Sublingual immunotherapy for cow's milk protein allergy: a preliminary report

1 reference

12 December 2020

Rush oral immunotherapy in children with persistent cow's milk allergy

1 reference

12 December 2020

A protocol for oral desensitization in children with IgE-mediated cow's milk allergy

1 reference

12 December 2020

Treatment of pollen allergy using the cutaneous checker square method of Blamoutier and Guibert

1 reference

12 December 2020

Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge

1 reference

12 December 2020

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber

1 reference

12 December 2020

Transcutaneous immunization: a human vaccine delivery strategy using a patch

1 reference

12 December 2020

Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial

1 reference

12 December 2020

Clinical efficacy and immune regulation with peanut oral immunotherapy

1 reference

12 December 2020

Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial

1 reference

12 December 2020

Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy.

1 reference

12 December 2020

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy

1 reference

12 December 2020

Medicine: Seasonal Hay Fever-Some Problems in Treatment.

1 reference

12 December 2020

Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Birch-apple syndrome treated with birch pollen immunotherapy

1 reference

12 December 2020

HLA-DR restricted peptide candidates for bee venom immunotherapy

1 reference

12 December 2020

Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results

1 reference

12 December 2020

Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults

1 reference

12 December 2020

Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma

1 reference

12 December 2020

Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects

1 reference

12 December 2020

Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction

1 reference

12 December 2020

Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract

1 reference

12 December 2020

TSLP: from allergy to vaccine adjuvant

1 reference

12 December 2020

Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity

1 reference

12 December 2020

Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis.

1 reference

12 December 2020

House dust mite sublingual immunotherapy: results of a US trial.

1 reference

12 December 2020

Health economics of allergen-specific immunotherapy in the United States

1 reference

12 December 2020

Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract

1 reference

12 December 2020

[Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route]

1 reference

12 December 2020

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

1 reference

12 December 2020

IL-33 and ST2 in Atopic Dermatitis: Expression Profiles and Modulation by Triggering Factors

1 reference

12 December 2020

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier

1 reference

12 December 2020

Skin immune sentinels in health and disease

1 reference

12 December 2020

Oral specific hyposensitization in the management of patients allergic to food

1 reference

12 December 2020

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

1 reference

12 December 2020

SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

1 reference

12 December 2020

Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens

1 reference

12 December 2020

Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems

1 reference

12 December 2020

Modification of a major peanut allergen leads to loss of IgE binding

1 reference

12 December 2020

Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy

1 reference

12 December 2020

Allergen-specific oral immunotherapy for peanut allergy

1 reference

12 December 2020

Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects

1 reference

12 December 2020

Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1

1 reference

12 December 2020

Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis

1 reference

12 December 2020

Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses

1 reference

12 December 2020

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs

1 reference

12 December 2020

Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract

1 reference

12 December 2020

Intralymphatic immunotherapy

1 reference

12 December 2020

Profilin desensitization in two patients with plant-derived food allergy

1 reference

12 December 2020

Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study

1 reference

12 December 2020

How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint

1 reference

12 December 2020

Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study

1 reference

12 December 2020

Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling

1 reference

12 December 2020

Oral desensitization in children with cow's milk allergy

1 reference

12 December 2020

Children's compliance with allergen immunotherapy according to administration routes

1 reference

12 December 2020

Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract

1 reference

12 December 2020

Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial

1 reference

12 December 2020

Oral food desensitization in children with IgE-mediated hen’s egg allergy: a new protocol with raw hen’s egg

1 reference

12 December 2020

High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens.

1 reference

12 December 2020

Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1

1 reference

12 December 2020

Oral rush desensitization to cow milk. Following of desensitized patients during three years.

1 reference

12 December 2020

Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats

1 reference

12 December 2020

Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy

1 reference

12 December 2020

Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: a case report

1 reference

12 December 2020

Ensuring vaccine safety in immunization programmes--a WHO perspective

1 reference

12 December 2020

Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the

1 reference

12 December 2020